摘要
目的探讨美沙拉嗪缓释片维持治疗缓解期溃疡性结肠炎(Ulcerative colitis,UC)的疗效及安全性。方法选取在我院接受治疗的缓解期溃疡性结肠炎患者126例,按数字表法随机分为试验组和对照组,每组均63例。对照组采用传统保守治疗方式维持治疗,试验组则在传统维持治疗基础上给予美沙拉嗪缓释片治疗。对比两组维持治疗后临床总有效率、疾病活动指数(DAI)、IL-6、IL-8及TNF-α水平变化、服药不良反应发生情况以及UC复发情况。结果试验组临床治疗总有效率(98.41%)、DAI(3.55±1.20)分、IL-6(100.18±25.14)ng/L、IL-8(159.88±34.85)ng/L、TNF-α(80.11±21.41)ng/L水平,以及UC复发率(1.59%)均明显优于对照组临床总有效率(52.38%)、DAI(4.29±1.33)分、IL-6(121.21±26.01)ng/L、IL-8(187.68±37.08)ng/L、TNF-α水平以及UC复发率(23.81%),统计学上有意义(P<0.05);治疗后,两组不良反应发生率差异比较,无统计学意义(P>0.05)。结论采用美沙拉嗪缓释片治疗缓解期UC患者,可进一步抑制UC患者炎症反应,患者各项指标均有明显改善,临床不适症状消失,对疾病维持治疗效果较显著,减少缓解期UC复发率,且药物副作用少,有助于患者恢复,安全性较好。
Objective To evaluate the clinical efficacy and safety of maintenance therapy with mesalazine sustained-release tablets in treatment of ulcerative colitis patients at remission. Methods A total of 126 patients with ulcerative colitis at remission period were recruited from our hospital and were equally divid-ed into experimental group and control group, with 63 cases in each group. Control group was given conven-tional maintenance therapy, while experimental group received mesalazine sustained-release tablet based on conventional maintenance therapy. The overall response rate, DAI index, interleukin-6, interleukin-8 and tu-mor necrosis factor-αlevels, adverse events and ulcerative colitis relapse rate in the two groups were com-pared after treatment. Results The overall response rate （98.41%）, DAI （3.55 ± 1.20） points, interleukin-6 （100.18 ± 25.14） ng/L, interleukin-8 （159.88 ± 34.85） ng/L, tumor necrosis factor-α（80.11 ± 21.41） ng/L , as well as ulcerative colitis relapse rate （1.59%） in the experimental group were significantly better than the over-all response rate （52.38%）, DAI （4.29 ± 1.33） points, interleukin-6 （121.21 ± 26.01） ng/L, interleukin-8 （187.68 ± 37.08） ng/L, tumor necrosis factor-αlevels and ulcerative colitis relapse rate （23.81%） in control group （P〈0.05）. There was no significant difference in the incidence of adverse reactions between two groups after treatment （P〉0.05）. Conclusion Mesalazine sustained-release tablet can inhibit inflammatory response, improve clinical and laboratory parameters. Therefore, this therapy is effective and safe.
出处
《现代消化及介入诊疗》
2016年第1期28-31,共4页
Modern Interventional Diagnosis and Treatment in Gastroenterology
关键词
缓解期
有效性
美沙拉嗪
安全性
UC
Remission
Effectiveness
Mesalazine
Ulcerative colitis
Safety
